Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266

Watchlist Manager
Suzhou Zelgen Biopharmaceuticals Co Ltd Logo
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
Watchlist
Price: 67.99 CNY -0.89% Market Closed
Market Cap: 18B CNY
Have any thoughts about
Suzhou Zelgen Biopharmaceuticals Co Ltd?
Write Note

Suzhou Zelgen Biopharmaceuticals Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Suzhou Zelgen Biopharmaceuticals Co Ltd
Income from Continuing Operations Peer Comparison

Comparables:
6160
603392
002252
300122
300896

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
Income from Continuing Operations
-ÂĄ295.1m
CAGR 3-Years
2%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Income from Continuing Operations
-ÂĄ6.7B
CAGR 3-Years
16%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Income from Continuing Operations
ÂĄ1.2B
CAGR 3-Years
22%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Income from Continuing Operations
ÂĄ1.8B
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
23%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Income from Continuing Operations
ÂĄ6B
CAGR 3-Years
-6%
CAGR 5-Years
26%
CAGR 10-Years
48%
Imeik Technology Development Co Ltd
SZSE:300896
Income from Continuing Operations
ÂĄ1.9B
CAGR 3-Years
62%
CAGR 5-Years
74%
CAGR 10-Years
N/A

See Also

What is Suzhou Zelgen Biopharmaceuticals Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
-295.1m CNY

Based on the financial report for Dec 31, 2023, Suzhou Zelgen Biopharmaceuticals Co Ltd's Income from Continuing Operations amounts to -295.1m CNY.

What is Suzhou Zelgen Biopharmaceuticals Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
8%

Over the last year, the Income from Continuing Operations growth was 39%. The average annual Income from Continuing Operations growth rates for Suzhou Zelgen Biopharmaceuticals Co Ltd have been 2% over the past three years , 8% over the past five years .

Back to Top